| 1 |
Blakely C,Jahan T.Emerging antiangiogenic therapies for non-small-cell lung cancer[J].Expert Rev Anticancer Ther,2011,11(10) : 1607-1618.
|
| 2 |
Folkman J.Tumor angiogenesis:therapeutic implication[J].N Engl J Med,1971,285(21), 1182-1186.
|
| 3 |
O’Reilly MS,Boehm T,Shing Y, et al. Endostatin:an endogenous inhibitor of angiogenesis and tumor growth[J].Cell, 1997, 88(2): 277-285.
|
| 4 |
Lazarus A,Keshet E. Vascular endothelial growth factor and vascular homeostasis[J]. Proc Am Thorac Soc,2011,8(6) : 508-511.
|
| 5 |
Folkman J.Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action[J].Expt Cell Res,2006,312(5):594-607.
|
| 6 |
Jain RK,di Tomaso E,Duda DG,et al.Angiogenesis in brain tumors[J].Nat Rev Neurosci,2007,8(8):610-612.
|
| 7 |
Hanahan D,Folkman J.Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis[J].Cell,1996,86(3):353-364.
|
| 8 |
Arkudas A,Tjiswi J,Bleiziffer O,et al.Fibrin gel-immobilized VEGF and Bfgf efficiently stimulate angiogenesis in the AV loop model[J],mol Med,2007,13(9-10):480-487.
|
| 9 |
Cele P,Yonemitsu Y.Vascular endothelial growth factor-basic science and its clinical implications[J].Pathophysiology,2004,11(2):69-75.
|
| 10 |
Achen MG,Stacker SA. Molecular control of lymphatic metastasis[J].Ann N Y Acad Sci,2008,31(11) : 225-234.
|
| 11 |
Rafii S,Lyden D,Benezra R,et al.Vascular and haematopoietic stem cells:novel targets for antiangiogenesis therapy[J]. Nat Rev Cancer, 2002,2(11):826-835.
|
| 12 |
李永丽,蔡曦光.血管内皮生长因子及其受体与肺癌的治疗进展[J]. 医学综述,2013, 19(2):272-274.
|
| 13 |
Folkman J.Antiangiogenesis: new concept for therapy of solid tumors[J].Ann Surg,1972,175(3):409-416.
|
| 14 |
Eberhard A,Kahlert S,Goede V, et al. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies[J]. Cancer Res,2000,60(5):1388-1393.
|
| 15 |
Fukumura D,Jain RK.tumor microvasculature and microenvironment:targets for antiangionensis and normalization[J].Microvasc Res,2007,74(2-3):72-84.
|
| 16 |
刘臻臻,罗琪.肿瘤血管靶向治疗策略的新进展[J].世界华人消化杂志,2010,18(27):2889-2893.
|
| 17 |
Reck M. Examining the safety profile of angiogenesis inhibitors: implications for clinical practice[J]Target Oncol,2010,5 (4) :257-267.
|
| 18 |
Feige JJ.Tumor angiogenesis: recent progress and remaining challenges[J].Bull Cancer, 2010,97(11) :1305-1310.
|
| 19 |
Braghiroli MI,Sabbaga J,Hoff PM.Bevacizumab: overview of the literature[J].Expert Rev Anticancer Ther,2012,12(5) : 567-580.
|
| 20 |
Hersey P,Sosman J,O'Day S,et al.A randomized phase 2 study of etaracizumab,a monoclonal antibody against integrin alpha(v)beta(3),+or-dacarbazine in patients with stage IV metastatic melanoma[J].Cancer.2010,116(6):1526-1534.
|
| 21 |
洪滨,王婉茹.恩度与化疗联合治疗非小细胞肺癌疗效观察[J].临床肺科杂志,2012, 17(11):2046-2047.
|
| 22 |
王蕾,黄兴,刘晓洪,等.重组人血管内皮抑素联合NP方案治疗晚期非小细胞肺癌[J].现代肿瘤医学,2010,18(8) : 1531-1532.
|
| 23 |
郑青平,倪秉强,罗展雄,等.重组人血管内皮抑素联合放化疗在非小细胞肺癌的临床观察[J].实用预防医学,2011,18(9):1713-1715.
|
| 24 |
Itasaka S,Komaki R,Herbst RS, et al. Endostatin improves radiore-sponse and blocks tumor revascularization after radiation therapy forA531 xenografts in mice[J]. Int J Radiat Oncol Biol Phys,2007,67(3):870-878.
|
| 25 |
Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy:a new paradigm for combination therapy[J]. Nature Med,2001,7(9):987-989.
|
| 26 |
Tong RT.Boucher Y.Kozin SV Vascular normalization by vascular endothelial growth factor receptor2 blockade induces a pressure gradient across the vasculature and improves drug penetration intumors[J].Cancer Res,2004,64(11):3731-3736.
|
| 27 |
Aggarwal C,Somaiah N,Simon G.Antiangiogenic agents in themanagement of non-small cell lung cancer: where do we stand now and where are we headed?[J].Cancer Biol Ther,2012,13 (5) :247-263.
|